AQUESTIVE THERAPEUTICS INC. - COMMON STOCK

Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET

25 апр 2024 07:00:00 Источник Nasdaq GlobeNewswire

Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology

12 апр 2024 15:01:00 Источник Nasdaq GlobeNewswire

Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive

01 апр 2024 07:00:00 Источник Nasdaq GlobeNewswire

Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock

25 мар 2024 07:00:25 Источник Nasdaq GlobeNewswire

Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock

19 мар 2024 20:49:43 Источник Nasdaq GlobeNewswire

Aquestive Therapeutics Announces Proposed Public Offering of Common Stock

19 мар 2024 15:01:00 Источник Nasdaq GlobeNewswire

Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting

14 мар 2024 16:23:20 Источник Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

05 мар 2024 16:05:49 Источник Nasdaq GlobeNewswire

Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET

21 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire

Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data at the 2024 AAAAI Annual Meeting

15 фев 2024 07:00:35 Источник Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Conference

30 янв 2024 07:00:27 Источник Nasdaq GlobeNewswire

Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual Film

05 дек 2023 07:00:00 Источник Nasdaq GlobeNewswire

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting

10 ноя 2023 07:00:10 Источник Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

06 ноя 2023 15:37:36 Источник Nasdaq GlobeNewswire

Aquestive Therapeutics Completes $45 Million Debt Refinancing

02 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire

Aquestive Therapeutics to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 6 and Host Conference Call on November 7 at 8:00 a.m. ET

31 окт 2023 07:00:00 Источник Nasdaq GlobeNewswire

Aquestive Therapeutics Provides Business Update

09 окт 2023 07:00:00 Источник Nasdaq GlobeNewswire

Aquestive Therapeutics Reaffirms Timeline and Pathway for Anaphylm™ (epinephrine) Sublingual Film

20 сен 2023 08:04:50 Источник Nasdaq GlobeNewswire

Aquestive Therapeutics Receives FDA Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film in Pediatric Patients and Assignment of Prescription Drug User Fee Act (PDUFA) Date

11 сен 2023 07:00:01 Источник Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

23 авг 2023 07:00:42 Источник Nasdaq GlobeNewswire